A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Phase 1 Terminated
42 enrolled
(VELA) Study of BLU-222 in Advanced Solid Tumors
Phase 1 Terminated
50 enrolled
REACT
Phase NA Terminated
51 enrolled 4 charts
PDL1x41BB
Phase 1 Terminated
160 enrolled
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
Phase 1/2 Terminated
13 enrolled 24 charts
Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer
Phase 2 Terminated
11 enrolled 11 charts
Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer
Phase 1/2 Terminated
7 enrolled 11 charts
Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
Phase 2 Terminated
22 enrolled 5 charts
Efficacy and Safety of OncoGelâ„¢ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer
Phase 2 Terminated
137 enrolled 9 charts
ICE-CANCER
Phase NA Terminated
1 enrolled 2 charts
Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus
Phase 2 Terminated
8 enrolled 5 charts
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
Phase 1/2 Terminated
15 enrolled 5 charts
Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
Phase 2 Terminated
4 enrolled
Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers
Phase 2 Terminated
5 enrolled 11 charts
Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery
Phase 2 Terminated
19 enrolled 4 charts
Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy
Phase 2 Terminated
2 enrolled 6 charts
Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery
Phase 2 Terminated
3 enrolled 5 charts
Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy
Phase 2 Terminated
1 enrolled 5 charts
Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors
Phase 2 Terminated
60 enrolled
Radiation Therapy, Pemetrexed Disodium, and Carboplatin in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery
Phase 2 Terminated
27 enrolled 6 charts
Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer
Phase 1 Terminated
23 enrolled
Study of Additive Omega-3 Fish Oil to Palliative Chemotherapy to Treat Oesophagogastric Cancer
Phase 2 Terminated
21 enrolled
S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer
Phase 2 Terminated
22 enrolled 9 charts
Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer
Phase 1/2 Terminated
Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery
Phase 2 Terminated
30 enrolled
FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
Phase 2 Terminated
20 enrolled
Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction
Phase 2 Terminated
50 enrolled
Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer
Phase 2 Terminated
Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction
Phase 1 Terminated
9 enrolled